TransMedics Group stock holds near model value as analysts stay positive

TransMedics Group stock (ISIN US89366D3075) is trading close to its assessed fair value, with the shares at USD 86.42 on September 20, 2026 and a key Buy rating from Needham still in place as of September 11, 2026. According to Investing.com, Needham currently sees upside to USD 106.00 per share, underlining a constructive view on the company’s prospects.

Analyst targets frame upside potential

The most recent analyst data show that Needham maintains a Buy recommendation on TransMedics Group stock with a price target of USD 106.00 as of September 11, 2026, implying an upside of about 22.7 percent compared with the closing level of USD 86.42 on September 20, 2026. According to Investing.com, other houses such as UBS and Stifel currently rate the stock Hold, with targets of USD 77.00 and USD 65.00 respectively as of August 5, 2026, highlighting a spread of views but still placing the shares within a structured target range.

A quantitative perspective on valuation comes from Faircurve, which models a fair value for TransMedics Group stock at USD 86.72 against the latest close of USD 86.42, a gap of only 0.3 percent. As Faircurve reports in its September 2026 healthcare sector overview, TransMedics Group appears broadly fairly valued on their model, with a market value around USD 3.0 billion as of mid-September 2026.

Price level and trading range

On the market side, TransMedics Group stock closed at USD 86.42 on Nasdaq on September 20, 2026, with the same level cited as the prior close, indicating a stable end-of-day mark. Per data cited by Reuters, the intraday range on that date ran between USD 85.01 and USD 87.98, giving investors an idea of the volatility band the stock traded in during the session.

The wider 52-week picture shows a substantial corridor. As of September 20, 2026, TransMedics Group stock has traded over the past year in a range between a low of USD 60.10 and a high of USD 156.00, according to Investing.com. With the current price at USD 86.42, the shares sit well above the 52-week low but far below the high, illustrating both the recovery from earlier lows and the distance to the peak levels that were previously reached.

Market value and investor perspective

The company’s market capitalization now stands at around USD 3.0 billion, based on the USD 86.42 share price and share count data reported by Investing.com for September 20, 2026. For investors, that market value places TransMedics Group firmly in the mid-cap bracket of the medical devices space, where both growth potential and volatility typically go hand in hand.

Trading activity has also been robust recently. In pre-market indications mentioned by Investing.com, TransMedics Group stock was quoted at USD 87.50 with a small decrease of 0.84 points or 0.97 percent and a modest pre-market volume of around 550 shares, underlining that the stock continues to attract trading interest even outside regular hours.

Fundamental backdrop and valuation context

While detailed quarterly figures are not highlighted in this week’s snapshot sources, the valuation context remains central. The Faircurve model, which compares last close to fair value across healthcare names, shows TransMedics Group stock at USD 86.42 versus a model fair value of USD 86.72 in its September 2026 sector list, implying a near one-to-one alignment between price and modeled intrinsic value. As Faircurve notes, that small 0.3 percent gap suggests that, at current levels, the market broadly agrees with their fair-value assessment rather than pricing in extreme optimism or pessimism.

The spread between Needham’s USD 106.00 target and the Faircurve fair value of USD 86.72 also offers a numerical way to think about expectations. Needham’s target is about 22.3 percent above the quantitative fair value, while the stock itself trades only slightly below that fair value. For investors, this combination of a near fair-value market price and an above-fair-value analyst target often highlights a case where operational execution and upcoming catalysts could justify multiple expansion or sustained earnings growth over time.

Risk factors and rating differences

The differing analyst stances also point to risk considerations. According to the overview on Investing.com, UBS and Stifel see the stock as a Hold with price targets of USD 77.00 and USD 65.00, respectively, as of August 5, 2026. Compared with the September 20, 2026 close of USD 86.42, the UBS target lies about 10.9 percent below the current price, while the Stifel target is roughly 24.8 percent lower, expressing more cautious views on valuation or risk.

This range of targets from USD 65.00 to USD 106.00 sets a corridor of plus or minus roughly 24 to 22 percent around the actual price, underlining that while the consensus does not point to extreme mispricing, individual houses still weigh execution risks, competitive dynamics in organ transportation technologies and broader market volatility differently. For investors watching TransMedics Group stock, the key is therefore to link these numbers back to the company’s ability to grow revenue, manage margins and expand its platform over the coming quarters.

TransMedics Group stock price snapshot

At the latest completed trading day referenced in the available data, TransMedics Group stock closed at USD 86.42 on Nasdaq as of September 20, 2026, with an intraday range between USD 85.01 and USD 87.98 and a 52-week corridor stretching from USD 60.10 to USD 156.00. That places the current level clearly above the 52-week low but far below the high, leaving room for both potential recovery and renewed volatility depending on how future results and guidance from the company shape investor expectations.

More news and analyses on TransMedics Group stock